Identifying the Target Population for Primary Respiratory Syncytial Virus Two-Step Prevention in Infants: Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN).
RSV
bronchiolitis
lower respiratory tract infection
monoclonal antibody
predictive score
primary prevention
public health
vaccines
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
06 May 2022
06 May 2022
Historique:
received:
31
03
2022
revised:
29
04
2022
accepted:
29
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection- related hospitalisations in infants (RSVh). Most of these infants are younger than 6 months old with no known risk factors. An efficient RSVh prevention program should address both mothers and infants, relying on Non-Pharmaceutical (NPI) and Pharmaceutical Interventions (PI). This study aimed at identifying the target population for these two interventions. Laboratory-confirmed RSV-infected infants hospitalised during the first 6 months of life were enrolled from the Hospices Civils de Lyon birth cohort (2014 to 2018). Clinical variables related to pregnancy and birth (sex, month of birth, birth weight, gestational age, parity) were used for descriptive epidemiology, multivariate logistic regression, and predictive score development. Overall, 616 cases of RSVh in 45,648 infants were identified. Being born before the epidemic season, prematurity, and multiparity were independent predictors of RSVh. Infants born in January or June to August with prematurity and multiparity, and those born in September or December with only one other risk factor (prematurity or multiparity) were identified as moderate-risk, identifying the mothers as candidates for a first-level NPI prevention program. Infants born in September or December with prematurity and multiparity, and those born in October or November were identified as high-risk, identifying the mothers and infants as candidates for a second-level (NPI and PI) intervention. It is possible to determine predictors of RSVh at birth, allowing early enrollment of the target population in a two-level RSV prevention intervention.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection- related hospitalisations in infants (RSVh). Most of these infants are younger than 6 months old with no known risk factors. An efficient RSVh prevention program should address both mothers and infants, relying on Non-Pharmaceutical (NPI) and Pharmaceutical Interventions (PI). This study aimed at identifying the target population for these two interventions.
METHODS
METHODS
Laboratory-confirmed RSV-infected infants hospitalised during the first 6 months of life were enrolled from the Hospices Civils de Lyon birth cohort (2014 to 2018). Clinical variables related to pregnancy and birth (sex, month of birth, birth weight, gestational age, parity) were used for descriptive epidemiology, multivariate logistic regression, and predictive score development.
RESULTS
RESULTS
Overall, 616 cases of RSVh in 45,648 infants were identified. Being born before the epidemic season, prematurity, and multiparity were independent predictors of RSVh. Infants born in January or June to August with prematurity and multiparity, and those born in September or December with only one other risk factor (prematurity or multiparity) were identified as moderate-risk, identifying the mothers as candidates for a first-level NPI prevention program. Infants born in September or December with prematurity and multiparity, and those born in October or November were identified as high-risk, identifying the mothers and infants as candidates for a second-level (NPI and PI) intervention.
CONCLUSIONS
CONCLUSIONS
It is possible to determine predictors of RSVh at birth, allowing early enrollment of the target population in a two-level RSV prevention intervention.
Identifiants
pubmed: 35632484
pii: vaccines10050729
doi: 10.3390/vaccines10050729
pmc: PMC9147066
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pediatr Infect Dis J. 1999 Mar;18(3):223-31
pubmed: 10093942
J Infect. 2019 Jun;78(6):468-475
pubmed: 30817978
Neonatal Netw. 2012 Nov-Dec;31(6):357-68
pubmed: 23134643
J Infect Dis. 2022 Jan 12;:
pubmed: 35023567
Euro Surveill. 2019 Jan;24(1):
pubmed: 30621817
Sci Rep. 2021 May 21;11(1):10684
pubmed: 34021214
Vaccine. 2021 Sep 15;39(39):5490-5498
pubmed: 34454783
Curr Med Res Opin. 2009 Jul;25(7):1585-91
pubmed: 19469698
Lancet Infect Dis. 2018 Oct;18(10):e295-e311
pubmed: 29914800
Paediatr Respir Rev. 2004;5 Suppl A:S119-26
pubmed: 14980256
Pediatr Infect Dis J. 2006 Mar;25(3):201-7
pubmed: 16511380
J Infect Dis. 2021 Mar 3;223(5):737-739
pubmed: 33350442
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
J Pediatr. 2003 Nov;143(5 Suppl):S112-7
pubmed: 14615709
BMC Infect Dis. 2021 Aug 2;21(1):730
pubmed: 34340679
Eur J Pediatr. 2007 Dec;166(12):1267-72
pubmed: 17308898
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30547-30553
pubmed: 33168723
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Respir Res. 2008 Dec 08;9:78
pubmed: 19063742
Lancet. 2012 Jun 9;379(9832):2162-72
pubmed: 22682464
PLoS One. 2013;8(3):e59161
pubmed: 23554987
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296674
Am J Respir Crit Care Med. 2002 May 1;165(9):1285-9
pubmed: 11991880
PLoS One. 2014 Feb 26;9(2):e89186
pubmed: 24586581
N Engl J Med. 2020 Jul 30;383(5):415-425
pubmed: 32726528
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Am J Epidemiol. 1991 Jun 1;133(11):1135-51
pubmed: 2035517
Pediatrics. 2011 Jan;127(1):35-41
pubmed: 21187309
Vaccine. 2018 Oct 29;36(45):6591-6593
pubmed: 30266485
Arch Dis Child. 2003 Dec;88(12):1065-9
pubmed: 14670770
N Engl J Med. 2020 Jul 30;383(5):426-439
pubmed: 32726529
Pediatrics. 2021 Apr;147(4):
pubmed: 33737374
Curr Opin Anaesthesiol. 2016 Dec;29(6):717-726
pubmed: 27536997
Prev Vet Med. 2000 May 30;45(1-2):23-41
pubmed: 10802332
Med Decis Making. 2008 Jul-Aug;28(4):471-80
pubmed: 18556643